Skingenix, Inc, a leader in dermal regeneration technologies, is currently pursuing a number of indications under an Investigational New Drug Application (IND) for their investigational product (MW-III) in the USA. The Company has recently completed under IND, a Phase II randomized and controlled multicenter clinical study to assess the safety and efficacy of their investigational product in patients with Diabetic Foot Ulcers (DFU) in the USA. Other indications such as burn injuries, venous stasis ulcers and pressure ulcers are being pursued.
Skingenix, Inc. is open to potential investors who are interested in being a part of its growth and success. Working together with motivated, talented, goal oriented, and highly experienced individuals at Skingenix with the guidance of a strong leadership of the management team, investors are encouraged to join the Skingenix family.